Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders

被引:4
作者
Khurana, Mallika [1 ]
Rahman, Syed Obaidur [2 ]
Najmi, Abul Kalam [2 ]
Pottoo, Faheem Hyder [3 ]
Akhtar, Sayeed [4 ]
机构
[1] Univ Tsukuba, Sch Comprehens Human Sci, Tsukuba Life Sci Innovat, 1 Chome 1-1 Tennodai, Tsukuba, Ibaraki 3058577, Japan
[2] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, Pharmaceut Med, New Delhi 110062, India
[3] Imam Abdulrahman Bin Faisal Univ, Coll Clin Pharm, Dept Pharmacol, POB 1982, Dammam 31441, Saudi Arabia
[4] King Khalid Univ, Coll Pharm, Dept Clin Pharm, Abha, Saudi Arabia
关键词
Neuroprotcomic Techniques; neurological Disorders; Alzheimer's disease; Parkinson's disease; multiple sclerosis; epilepsy; psychiatric disorders; Omics; MULTIPLE-SCLEROSIS PATIENTS; QUANTITATIVE PROTEOMIC ANALYSIS; ANTERIOR CINGULATE CORTEX; PLASMA APOLIPOPROTEIN A1; HUMAN SUBSTANTIA-NIGRA; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; PSYCHIATRIC-DISORDERS; PROTEIN BIOMARKERS;
D O I
10.2174/1389203721666201104130135
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Decades of research has mimed us with the very distinctive anatomy and physiology of our brain, and on the other hand, its complexity has always posed great difficulty in treating its dysfunction or damage. Understanding the brain under normal and, particularly in the diseased state, has always been very challenging and would have been impossible without proteomics. Neuroproteomic techniques have been extensively used for unraveling both dynamics and content of the proteome of our nervous system. This modern-day investigation and quantification of protein concentration and expression have given us a platform that enhances our knowledge on disease-associated processes and pathways modification and also leads to the identification of possible biomarkers that can he therapeutically targeted. With an increased interest in identifying and targeting possible hiomarkers, this article focuses on describing applications of the much discussed neuroproteomics, with a significant role in the disease pathogenesis of some very common neurological disorders. This article will collectively discuss the use and relevance of neuroproteomics in a range of neurological diseases, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and psychiatric disorders. We have also attempted to present the current successes and failures of the neuroproteomics approach on the results obtained from different clinical studies that targeted hiomarkers associated with any particular neurological disorder.
引用
收藏
页码:1146 / 1163
页数:18
相关论文
共 172 条
  • [1] Abdi F, 2006, J ALZHEIMERS DIS, V9, P293
  • [2] The epidemiology of ALS: a conspiracy of genes, environment and time
    Al-Chalabi, Ammar
    Hardiman, Orla
    [J]. NATURE REVIEWS NEUROLOGY, 2013, 9 (11) : 617 - 628
  • [3] Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia
    Albertini, Valentina
    Benussi, Luisa
    Paterlini, Anna
    Glionna, Michela
    Prestia, Annapaola
    Bocchio-Chiavetto, Luisella
    Amicucci, Giovanni
    Galluzzi, Samantha
    Adorni, Andrea
    Geroldi, Cristina
    Binetti, Giuliano
    Frisoni, Giovanni B.
    Ghidoni, Roberta
    [J]. ELECTROPHORESIS, 2012, 33 (24) : 3738 - 3744
  • [4] New Potential Serum Biomarkers in Multiple Sclerosis Identified by Proteomic Strategies
    Amin, Bushra
    Maurer, Andreas
    Voelter, Wolfgang
    Melms, Arthur
    Kalbacher, Hubert
    [J]. CURRENT MEDICINAL CHEMISTRY, 2014, 21 (13) : 1544 - 1556
  • [5] Label-Free Quantitative LC-MS Proteomics of Alzheimer's Disease and Normally Aged Human Brains
    Andreev, Victor P.
    Petyuk, Vladislav A.
    Brewer, Heather M.
    Karpievitch, Yuliya V.
    Xie, Fang
    Clarke, Jennifer
    Camp, David
    Smith, Richard D.
    Lieberman, Andrew P.
    Albin, Roger L.
    Nawaz, Zafar
    El Hokayem, Jimmy
    Myers, Amanda J.
    [J]. JOURNAL OF PROTEOME RESEARCH, 2012, 11 (06) : 3053 - 3067
  • [6] Anoctamin 2 identified as an autoimmune target in multiple sclerosis
    Ayoglu, Burcu
    Mitsios, Nicholas
    Kockum, Ingrid
    Khademi, Mohsen
    Zandian, Arash
    Sjoberg, Ronald
    Forsstrom, Bjorn
    Bredenberg, Johan
    Bomfim, Izaura Lima
    Holmgren, Erik
    Gronlund, Hans
    Guerreiro-Cacais, Andre Ortlieb
    Abdelmagid, Nada
    Uhlen, Mathias
    Waterboer, Tim
    Alfredsson, Lars
    Mulder, Jan
    Schwenk, Jochen M.
    Olsson, Tomas
    Nilsson, Peter
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (08) : 2188 - 2193
  • [7] Advances in motor neurone disease
    Baeumer, Dirk
    Talbot, Kevin
    Turner, Martin R.
    [J]. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2014, 107 (01) : 14 - 21
  • [8] Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology
    Baird, Alison L.
    Westwood, Sarah
    Lovestone, Simon
    [J]. FRONTIERS IN NEUROLOGY, 2015, 6
  • [9] Proteome analysis of human substantia nigra in Parkinson's disease
    Basso, M
    Giraudo, S
    Corpillo, D
    Bergamasco, B
    Lopiano, L
    Fasano, M
    [J]. PROTEOMICS, 2004, 4 (12) : 3943 - 3952
  • [10] Proteome analysis of mesencephalic tissues: evidence for Parkinson's disease
    Basso, M
    Giraudo, S
    Lopiano, L
    Bergamasco, B
    Bosticco, E
    Cinquepalmi, A
    Fasano, M
    [J]. NEUROLOGICAL SCIENCES, 2003, 24 (03) : 155 - 156